DIACEUTICS

CORPORATE OVERVIEW SEPTEMBER 2026

RYAN KEELING | CHIEF EXECUTIVE OFFICER | RYAN.KEELING@DIACEUTICS.COM
NICK ROBERTS | CHIEF FINANCIAL OFFICER | NICK.ROBERTS@DIACEUTICS.COM

DISCLAIMER AND FORWARD-LOOKING STATEMENTS

DIACEUTICS

Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the ("Company"). "Presentation" means this document, any oral presentation, any question and answer session and any written or oral material discuss ed, presented or distributed during the meeting. This Presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the "Group") or in any other entity, nor shall this Presentation or any part of it, or the fact of its Presentation, form the basis of, or be relied on in connection with, any contract or investment activity nor does it constitute a recommendation regarding the securities of the Group. Past performance, including the price at which the Company's securities have been bought or sold in the past and the past yield on the Company's securities, cannot be relied on as a guide to future performance. Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial advisor or independent legal counsel. Neither this Presentation nor any information contained in this Presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the Presentation to any other person in any jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation. Recipients of this Presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you. The information in this Presentation is confidential and proprietary to and is being submitted to you solely for your confidential use and with the explicit understanding that, without the prior written permission of the Company you will not release or discuss this Presentation, its existence, any of the information contained herein, or make any reproduction of or use this Presentation for any purpose. No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates, advisors and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discuss ed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this Presentation. No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this Presentation or any other written or oral information which has been or may be made available. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to the Presentation. No reliance whatsoever may be placed on the Presentation for any purpose. By accepting this Presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws. The information contained in this Presentation has not been independently verified. This Presentation is intended only for communications with investors.

Forward-Looking Statements :This Presentation may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this communication are based on numerous assumptions and the Company present and future business strategies and the environment in which the Company expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results , performance or achievements to be materially different from those expressed or implied by such forward-looking statements, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of the Company ability to control or estimate precisely, such as future market conditions , the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Company ability to obtain financing, changes in the political, social and regulatory framework in which the Company operates or in economic, technological or consumer trends or conditions. This Presentation does not constitute an invitation or inducement to engage in investment activity. Similarly, this Presentation does not constitute or form part of any offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, nor shall it (nor any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or investment decision in relation thereto.

The delivery of this Presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this Presentation since the time specified. None of the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this Presentation, whether as a result of new information, future events or otherwise. In giving this Presentation none of the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent. Certain industry and market data contained in this Presentation has been obtained from third party sources. Third party industry publications , studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications , studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein accordingly the Company, the Group, their affiliates and advisors and their respective directors, officers, partners, representatives, employees and agents, expressly disclaim, to the maximum extent permitted by law and regulation, any and all responsibility or liability as to the accuracy, completeness or reasonableness of the information provided.

In addition, certain of the industry, scientific and market data contained in this Presentation comes from the Company's own internal case studies, research and estimates based on the knowledge and experience of the Company's management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice.

By attending the Presentation you agree to be bound by the limitations above.

H1 2026 STRATEGIC AND COMMERCIAL HIGHLIGHTS

DIACEUTICS

+ Diaceutics continues to work with 18 of the top 20 global pharma companies, supporting 55 customers across 103 therapeutic brands.
+ Precision For All proposition expands the Company's market opportunity from traditional precision medicine into the broader universe of diagnostic-driven therapies.
+ Signal ARR has grown by 46% in the first 6 months of 2026 and is used across 55 brands (Jun-25: 36)
+ Continued investment in DXRX, proprietary data assets and AI-enabled analytics strengthened the Group's intelligence and engagement platform.
+ Repositioning launched to market, presenting Diaceutics as the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies.
+ Commercial and delivery model redesigned to support scale, clearer accountability, improved customer delivery and greater operating leverage.
+ Launch of dedicated Growth function to identify and develop opportunities outside the routes to market served by our core pharmaceutical commercial organization.

The Board remains confident in delivering against its 2026 expectations.

DIACEUTICS

H1 2026: OPERATIONAL HIGHLIGHTS

Metric	H1 2026	H1 2025
GLOBAL PHARMA	18 of 20	H1 2025: 18 of 20
CUSTOMERS	55	H1 2025: 50
AVE. NUMBER OF PEOPLE	205	H1 2025: 206
ENTERPRISE CUSTOMERS	10	H1 2025: 8
BRANDS	103	H1 2025: 89
RELAY (PMX) CUSTOMERS	2	H1 2025: 1
RELAY (PMX) ARR	£4.3m	H1 2025: £1.4m

	MARKET OPPORTUNITY	CURRENT PROGRESS
INCREASE ADOPTION IN PRECISION MEDICINE MARKET Actively upsell solutions to new and existing brands within the core precision medicine market and extend coverage of services throughout the commercialization lifecycle. Ultimately, look to embed Relay (PMx) with every customer brand.	**TAM $1.0bn** 400 brands	**Progressing to Plan** 73 brands up from 68
EXTEND OUR MARKET REACH INTO PRECISION FOR ALL Increase current market reach from precision medicine market into Precision For All – any therapies with diagnostically driven patient pathways.	**TAM $0.4bn** 700 brands	**Launched in 2025** 30 brands up from 21

Expanding our addressable markets and capturing more value

DIACEUTICS

H1 2026 FINANCIAL HIGHLIGHTS

- Revenue increased 20% to £17.5 million, or 22% on a constant currency basis.
- ARR increased 79% to £29.4 million, with NRR of 149% and gross ARR churn reduced to 6%.
- Order book increased 38% to £43.7 million, with £15.7 million contracted for H2 2026 delivery.
- Gross profit increased 23% to £14.9 million, with gross margin expanding to 85%.
- Adjusted EBITDA increased to £1.1 million, demonstrating emerging operating leverage.
- Positive free cash flow of £0.7 million; £8.1 million of cash and no debt – fully funded to deliver the organic growth strategy

*EBITDA is earnings before interest, tax, depreciation and amortization. Adjusted EBITDA removes share-based payment charges and once-off exceptional items.
**Annual Recurring Revenue (ARR) is the value of recurring subscription revenue at a specific point in time that is expectedto be recognized from contracts over the next twelve months.

STRONG ARR GROWTH DRIVES H2 REVENUE & PROFIT VISIBILITY

DIACEUTICS

REVENUE	ARR	ORDER BOOK	RECURRING REVENUE	ADJUSTED EBITDA	CASH / NET CASH
£17.5m	£29.4m	£43.7m	61%	£1.1m	£8.1m
+20% / vs £14.6m	+79% / vs £16.4m	+38% / vs £31.7m	+6 pp% / vs 55%	+£1.0 / vs £0.1m	vs £10.4m

REVENUE GROWTH



Reported +20% | Constant currency +22% | 3-yr CAGR 21%

ADJ EBITDA PROFITABILITY



Adj EBITDA £1.1m | Loss Before Tax £4.0m | Free Cash Flow £0.7m

(F) Denotes consensus estimates based on published analyst research. The Company neither endorses nor adopts these estimates, and they should not be regarded as Company guidance.

107% visibility on achieving FY 2026 median analyst consensus revenue estimates

INCREASING REVENUE QUALITY & VISIBILITY

DIACEUTICS

Recurring revenue increases 6 pp to 61% as ARR grows 79% and total order book grows 38%

REVENUE MIX



ARR MOVEMENT

TOTAL ORDER BOOK £43.7m
+38% / vs £31.7m

H2 CONTRACTED £15.7m
+74% / vs £9.0m

GROSS CHURN (Lost customers) -6%
+13 pp / vs -19%

NET REVENUE RETENTION 149%
+31 pp / vs 118%

Customer retention, brand growth and upsell of ARR products are driving quality and visibility

OPERATING LEVERAGE DRIVING PROFIT & CASH GROWTH

DIACEUTICS

Investing in marketing and sales enablement whilst realising scale in people costs





GROSS MARGIN 85% | vs 83%

ADJ. EBITDA MARGIN 6.0% | vs 0.4%

FREE CASH FLOW +£0.7m | vs -£2.4m

Priorities: Selected investments to facilitate organic growth, scale operating activities and costs, improve working capital cash conversion

DIACEUTICS BUSINESS MODEL

DIACEUTICS

We deliver solutions that help life sciences companies: Find the patient. Remove the barrier. Activate the physician. Improve therapy adoption. Measure the outcome.

01
PARTNER NETWORK
670 labs and hospitals contribute de-identified testing data and real-world diagnostic signals

02
DATA + AGENTIC AI MODEL
Diaceutics normalizes fragmented data, infers clinical intent and enriches it with agentic AI to create higher-value intelligence

03
SUBSCRIPTION SOLUTIONS
Insights are productized into subscription offerings and services, including Signal, Physician Engage and activation support

04
PHARMA ACTIONABILITY
Commercial, medical and market access teams use these products to identify opportunity, prioritize action and improve execution

05
CUSTOMER VALUE CREATION
More patients on therapy, stronger topline growth and lower cost-to-serve through a more effective model

WHY IT SCALES

Each new lab or hospital in the network improves coverage and solution quality

Reveal data asset can power multiple subscription products and service layers

Agentic AI increases speed, insight generation and operating leverage

Recurring subscriptions improve revenue visibility, resilience and compounding growth

Customer expansion creates both topline upside and a more efficient delivery model

DIACEUTICS MOAT

DIACEUTICS

PARTNER NETWORK → DIAGNOSTIC DATA → CLINICAL INTELLIGENCE → ACTIVATION → CUSTOMER OUTCOMES → DEEPER EMBEDDING

01 PARTNER NETWORK

670 labs & hospitals in the partner network

- Long-tail access beyond the major reference-lab networks
- It takes years to onboard a new lab data partner

02 PROPRIETARY DIAGNOSTIC DATA

Differentiated diagnostic signals across real patient journeys

- Testing and laboratory data reveal what claims alone cannot
- Curated into a proprietary data asset built for clinical intent and actionability

03 CLINICAL INTENT & ACTIONABILITY

From a diagnostic event to the next best commercial action

- Testing behavior helps identify clinical intent
- Integrated into the physician office workflow

04 EMBEDDED SUBSCRIPTION PRODUCTS

Signal · Physician Engage · Relay

- Subscription products embed insight into pharma workflows
- Relay deepens enterprise, multi-year customer relationships

05 AGENTIC AI SCALE ENGINE

AI agents enrich, interpret and operationalise fragmented data

- Faster insight generation and disease-model deployment
- Supports scale without linear growth in manual effort

06 CUSTOMER DISTRIBUTION ADVANTAGE

18 of top 20 pharma · 55 customers · 103 brands

- Customer distribution and breadth reinforce the moat
- More customers and brands create more product learning and deeper reach

WHAT IS PRECISION FOR ALL?

DIACEUTICS

PRECISION MEDICINE

Tailors treatment using molecular, genetic or biomarker information to identify the right patient for the right therapy.

PRECISION FOR ALL

Builds on precision medicine and extends the same logic to the broader universe of diagnosis-enabled therapies

PRECISION FOR ALL CREATES VALUE

Whenever diagnostic testing, patient identification, disease stratification or practice-gap detection changes commercial success.



PRECISION MEDICINE High-value, biomarker-defined subset ~250 PM brands (illustrative)

→

PRECISION FOR ALL Broader diagnosis-enabled therapy universe ~1,100 diagnosis-enabled therapies (illustrative)

Precision Medicine is the foundation. **Precision For All is the broader commercial category.**

PRODUCT LINEUP

DIACEUTICS

DXRX connects diagnostic intelligence with scientific engagement to turn insight into coordinated commercial action



DIAGNOSTIC-DRIVEN COMMERCIALIZATION

DIACEUTICS

IMPACT

Targeted commercialization is designed for the US healthcare market to deliver measurable outcomes by improving alignment to best-practice testing, supporting more informed physician decision-making and increasing the likelihood that eligible patients reach appropriate therapy.

100%

Increase in best practice testing

82%

of HCPS reported increased understanding of the disease

78%

of signaled & engaged HCPs have gone on to treat

DXRX targeted commercialization increases biopharma commercial prescriptions and **reduces commercialization budgets between 12-41%.**

Diaceutics is actively supporting two **Relay (formerly PMx) commercialization engagements** for US biopharma clients.

SIGNAL: CASE STUDY

How real-time diagnostic signals drove measurable commercial impact

DIACEUTICS

THE CHALLENGE

A pharma client needed to identify patients with a specific lung cancer mutation so it could target the right physicians and sales interactions more effectively.

THE INTERVENTION (activated week 27)

DXRX Signal was activated in Week 27, enabling real-time identification of eligible patients and more precise commercial outreach.

THE IMPACT

Patient starts doubled immediately at activation and the uplift was sustained over the following 18 months.



2.0x
Immediate uplift in patient starts

18 months
Sustained improvement

$350
ROI per $1 invested

Each additional patient was worth approximately $220k in average client revenue.

Patient starts doubled following activation, and the uplift was sustained over the following 18 months.

DIACEUTICS

PRECISION FOR ALL

Growth driven by customer success

SIGNIFICANT & GROWING MARKET OPPORTUNITY

- Biopharma are rapidly shifting to diagnosis-enabled healthcare to target better patient care, capture lost revenue and increase profitability

STRONG COMPETITIVE MOAT

- Comprehensive US lab partner network
- Proprietary multimodal healthcare data asset
- AI-enabled and scalable DXRX platform

COMPELLING VALUE PROPOSITION

- High ROI - $100 of additional customer revenue for every $1 spent on DXRX
- Blue-chip customers
- More patients identified
- Better testing & therapy adoption

HIGH-QUALITY REVENUE MODEL

- High growth ARR business
- Increasing multi-year revenue visibility
- High gross margin and profitable
- Strong balance sheet and fully funded to support growth

PROVEN EXECUTION

- 18 of top 20 pharma
- 103 therapeutic brands
- Two Relay (PMx) commercialization engagements
- Proven commercial execution
- Founder led management

TEAM & CONTACTS

Ryan Keeling
Chief Executive Officer

Nick Roberts
Chief Financial Officer

investorrelations@diaceutics.com

DXRX LN / DXRX.L

Hayley Palmer
Canaccord Genuity
hpalmer@cgf.com

Julie Simmonds
Panmure Liberum
julie.simmonds@panmureliberum.com

Chris Glasper
Singer Capital Markets
chris.glasper@singercm.com

Christian Glennie
Stifel
christian.glennie@stifel.com

Natalia Webster
RBC Capital Markets
natalia.webster@rbccm.com

DIACEUTICS

APPENDIX

PROFIT AND LOSS (P&L) AND BALANCE SHEET
STATEMENT OF CHANGES IN EQUITY (SOCIE) AND CASH FLOW

DIACEUTICS

P&L AND BALANCE SHEET

	Six months to 30-Jun-26 (Unaudited) £000's	Six months to 30-Jun-25 (Unaudited) £000's	Year ended 31-Dec-25 (Audited) £000's
Revenue	**17,456**	14,564	38,437
Cost of sales	**-2,595**	-2,477	-6,958
Gross profit	**14,861**	12,087	31,479
Administrative expenses	**-18,941**	-15,435	-31,691
Other operating income	**64**	169	255
Operating (loss)/profit	**-4,016**	-3,179	43
Finance income	**74**	195	317
Finance costs	**-26**	-29	-58
(Loss)/profit before tax	**-3,968**	-3,013	302
Income tax credit/(charge)	**1,199**	612	-205
(Loss)/profit for the financial period	**-2,769**	**-2,401**	97

	30-Jun-26 (Unaudited) £000's	30-Jun-25 (Unaudited) £000's	31-Dec-25 (Audited) £000's
ASSETS			
Non-current assets			
Intangible assets	**15,746**	15,362	16,080
Right of use assets	**2,027**	1,090	1,108
Property, plant and equipment	**493**	621	556
Deferred tax asset	**4,482**	2,886	2,902
	22,748	19,959	20,646
Current assets			
Trade and other receivables	**20,944**	13,512	21,256
Income tax receivable	**359**	568	762
Cash and cash equivalents	**8,102**	10,384	7,344
	29,405	24,464	29,362
TOTAL ASSETS	**52,153**	**44,423**	50,008
EQUITY AND LIABILITIES			
Equity			
Equity share capital	**170**	170	170
Treasury shares	**-312**	-312	-312
Translation reserve	**-843**	-1,266	-980
Profit and loss account	**39,735**	38,649	41,602
TOTAL EQUITY	**38,750**	**37,241**	40,480
Non-current liabilities			
Lease liability	**1,818**	905	882
Provision for dilapidations	**74**	93	95
	1,892	998	977
Current liabilities			
Trade and other payables	**11,184**	5,951	8,254
Lease liability	**276**	229	270
Income tax payable	**51**	4	27
	11,511	6,184	8,551
TOTAL LIABILITIES	**13,403**	**7,182**	9,528
TOTAL EQUITY AND LIABILITIES	**52,153**	**44,423**	50,008

SOCIE AND CASH FLOW

	Equity share capital	Treasury shares	Translation reserve	Profit and loss account	Total equity
	£000's	*£000's*	*£000's*	*£000's*	*£000's*
At 1 January 2025	**170**	**-312**	**-626**	**40,625**	**39,857**
Loss for the period	-	-	-	-2,401	-2,401
Other comprehensive loss	-	-	-640	-	-640
Share based payments	-	-	-	425	425
At 30 June 2025 (unaudited)	**170**	**-312**	**-1,266**	**38,649**	**37,241**
Profit for the period	-	-	-	2,498	2,498
Other comprehensive income	-	-	286	-	286
Share based payments	-	-	-	490	490
Deferred Tax Credit	-	-	-	-35	-35
At 31 December 2025 (audited)	**170**	**-312**	**-980**	**41,602**	**40,480**
At 1 January 2026	**170**	**-312**	**-980**	**41,602**	**40,480**
Loss for the period	-	-	-	-2,769	-2,769
Other comprehensive income	-	-	137	-	137
Share based payments	-	-	-	940	940
Deferred Tax Credit taken directly to equity	-	-	-	-38	-38
At 30 June 2026 (unaudited)	**170**	**-312**	**-843**	**39,735**	**38,750**

	Six months to 30-Jun-26 (Unaudited) £000's	*Six months to 30-Jun-25 (Unaudited) £000's*	*Year ended 31-Dec-25 (Audited) £000's*
Loss/(profit) before tax	**-3,968**	-3,013	302
Adjustments to reconcile loss before tax to net cash flows from operating activities			
Net finance income	**-48**	-164	-259
Amortisation of intangible assets	**3,118**	2,494	5,355
Research and development tax credits	**-**	-	-62
Depreciation of RoU asset and PPE	**240**	207	457
Decrease/(increase) in trade and other receivables	**1,178**	3,863	-5,151
Increase/(decrease) in trade and other payables	**1,917**	-3,139	643
Share based payments	**924**	425	915
Cash generated from operations	**3,361**	673	2,200
Tax paid	**-12**	-68	-1,021
Net cash inflow from operating activities	**3,349**	605	1,179
Investing activities			
Purchase of intangible assets and PPE	**-2,446**	-2,822	-6,448
Finance interest received	**74**	195	317
Net cash outflow from investing activities	**-2,372**	-2,627	-6,131
Financing activities			
Leasehold repayments	**-179**	-141	-333
Net cash outflow from financing activities	**-179**	-141	-333
Net increase/(decrease) in cash and cash equivalents	**798**	-2,163	-5,285
Net foreign exchange movements	**-40**	-197	-115
Opening cash and cash equivalents	**7,344**	12,744	12,744
Closing cash and cash equivalents	**8,102**	10,384	7,344